Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA approves Natrecor for treatment of congestive heart failure

Aug. 14, 2001

Zeltia and Ortho Biotech announce licensing agreement for ET-743

Aug. 14, 2001

Approval of Remodulin recommended by the FDA for pulmonary arterial hypertension

Aug. 14, 2001

First clinical trial of rhuCD40L in cancer patients completed

Aug. 14, 2001

Venlafaxine ER shows good long-term results in GAD patients

Aug. 14, 2001

New class of antibacterials reported by Ortho-McNeil

Aug. 14, 2001

New benzamidine derivatives with anticoagulant activity designed by Ajinomoto

Aug. 14, 2001

Ajinomoto patents new series of factor VII inhibitors

Aug. 14, 2001

Pfizer describes erythromycin A derivatives with antibacterial and antiprotozoal activity

Aug. 14, 2001

Rituximab tested as a treatment for chronic ITP

Aug. 14, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Wuxi Apptec insists it’s ‘not a Chinese military company’
BioWorld
Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.